Market Movers | Winners: IOVA, ITG, DNA | Losers: QURE, FICO, CLPT
A quiet day for the indexes hid extreme moves in single stocks that were weeks in the making.
The S&P 500 returned -0.2% and the Dow Jones Industrial Average returned -0.3%, while the Nasdaq-100 returned +0.2%. Beneath that quiet surface, the day’s biggest loser, uniQure (QURE), fell 37.3%. The central question is whether such an extreme move is a one-day event or the continuation of a trend.
Tuesday’s Market Winners
The 10 US-listed stocks in the Trefis coverage universe with the highest returns on the last trading day:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | IOVA | Iovance Biotherapeutics | 31.5% | 429.3% |
| 2 | ITG | ITG | 15.5% | n/a |
| 3 | DNA | Ginkgo Bioworks | 14.3% | 43.9% |
| 4 | CCL | Carnival Corporation | 13.4% | -16.5% |
| 5 | PWP | Perella Weinberg Partners | 11.8% | -4.3% |
| 6 | WRBY | Warby Parker | 11.4% | 26.1% |
| 7 | CSIQ | Canadian Solar | 10.8% | -51.4% |
| 8 | BE | Bloom Energy | 10.8% | 235.2% |
| 9 | MGNI | Magnite | 9.7% | 58.2% |
| 10 | RXRX | Recursion Pharmaceuticals | 8.9% | -1.5% |
Tuesday’s Market Losers
And the 10 US-listed stocks in the Trefis coverage universe with the lowest returns:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | QURE | uniQure | -37.3% | 2.4% |
| 2 | FICO | Fair Isaac | -26.5% | -63.5% |
| 3 | CLPT | ClearPoint Neuro | -23.1% | -14.0% |
| 4 | QNC | Quantum eMotion | -20.5% | -52.4% |
| 5 | INDP | Indaptus Therapeutics | -13.4% | -2.1% |
| 6 | WGS | GeneDx | -11.8% | -41.7% |
| 7 | CNTN | Canton Strategic | -11.5% | -21.5% |
| 8 | PIPR | Piper Sandler Cos | -9.7% | -21.9% |
| 9 | CTNM | Contineum Therapeutics | -9.7% | 0.6% |
| 10 | PS | Pershing Square | -9.5% | n/a |
Today’s largest moves extended month-long trends.
The day’s top gainer, Iovance Biotherapeutics (IOVA), returned +31.5%. This move built on prior strength, as the stock’s one-month return is +80.4%. Excluding today, it still gained +37.2% over the other sessions. The day’s weakest name, uniQure (QURE), shows the same pattern in reverse. Its -37.3% return today brought its one-month loss to -49.7%, and it had already lost 19.7% in the preceding weeks. Both companies reported recent revenue growth, with Iovance at 34.5% and uniQure at 30.2% over the last twelve months.
Movers Over The Last Week
Widening the window to five trading days, these are the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | KOD | Kodiak Sciences | 169.6% | 225.9% |
| 2 | SRZN | Surrozen | 81.7% | 41.5% |
| 3 | IOVA | Iovance Biotherapeutics | 35.8% | 429.3% |
| 4 | QMCO | Quantum | 28.1% | 409.5% |
| 5 | DNA | Ginkgo Bioworks | 27.6% | 43.9% |
| 6 | GRAL | GRAIL | 25.8% | 59.6% |
| 7 | PACB | Pacific Biosciences of California | 24.5% | -2.1% |
| 8 | PWP | Perella Weinberg Partners | 22.7% | -4.3% |
| 9 | FBYD | Falcons Beyond Global | 19.9% | -44.1% |
| 10 | WRBY | Warby Parker | 19.7% | 26.1% |
Losers
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | QURE | uniQure | -45.9% | 2.4% |
| 2 | KDK | Kodiak AI | -33.4% | -80.5% |
| 3 | FICO | Fair Isaac | -32.4% | -63.5% |
| 4 | CGEM | Cullinan Therapeutics | -29.7% | 47.1% |
| 5 | INDP | Indaptus Therapeutics | -28.6% | -2.1% |
| 6 | BYND | Beyond Meat | -28.5% | -66.5% |
| 7 | CTEV | Claritev | -26.5% | -49.4% |
| 8 | ALKT | Alkami Technology | -26.1% | -42.0% |
| 9 | ITG | ITG | -26.0% | n/a |
| 10 | CLPT | ClearPoint Neuro | -25.5% | -14.0% |
Movers Over The Last Month
And over the last 21 trading days, the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | INDP | Indaptus Therapeutics | 150.0% | -2.1% |
| 2 | KOD | Kodiak Sciences | 141.6% | 225.9% |
| 3 | CYPH | Cypherpunk Technologies | 88.9% | 178.4% |
| 4 | IOVA | Iovance Biotherapeutics | 80.4% | 429.3% |
| 5 | SVIA | Silvia | 72.5% | 8.5% |
| 6 | DNA | Ginkgo Bioworks | 71.8% | 43.9% |
| 7 | GRAL | GRAIL | 70.7% | 59.6% |
| 8 | MNTK | Montauk Renewables | 66.1% | 76.0% |
| 9 | VICR | Vicor | 54.8% | 165.2% |
| 10 | SDGR | Schrodinger | 54.0% | 69.6% |
Losers
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | ALMS | Alumis | -67.4% | -25.3% |
| 2 | XNDU | Xanadu Quantum Technologies | -54.6% | n/a |
| 3 | QURE | uniQure | -49.7% | 2.4% |
| 4 | FICO | Fair Isaac | -46.4% | -63.5% |
| 5 | KDK | Kodiak AI | -45.4% | -80.5% |
| 6 | CTEV | Claritev | -45.1% | -49.4% |
| 7 | IMUX | Immunic | -42.1% | 66.9% |
| 8 | ALHC | Alignment Healthcare | -41.9% | -59.9% |
| 9 | CXM | Sprinklr | -40.9% | -38.0% |
| 10 | BYND | Beyond Meat | -40.6% | -66.5% |
A large return is a starting point for research, not a conclusion.
The tables of market leaders and laggards shown earlier are a map of where attention and volatility were highest. They are not a set of instructions. A large percentage move, positive or negative, is simply a signal that something has changed. The disciplined next step is to investigate the business behind the ticker.
The next step is never to trade the list; it is to test it. Our Guidance Momentum screen shows which risers have management raising guidance behind them, and our Buy the Dip screen shows which of the fallers still generate the growth and cash that make a recovery plausible.
Volatility Is The Cost Of Owning Stocks. Concentration Makes It A Bill
Every name on these lists made a move big enough to notice. A diversified holder reads that as noise; a concentrated holder feels it as real money. The difference is not the stock, it is the portfolio around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb bad days, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Let the movers list remind you why diversification exists.